TOMI™ Signs Agreement to Support Continuing Expansion Into U.S. Healthcare Market

BEVERLY HILLS, Calif., Jan. 31, 2017 -- TOMI™ Environmental Solutions, Inc. (TOMI) (OTCQX:TOMZ), a global bacteria decontamination and infection prevention company, announced it signed an agreement with 41 North Partners to provide TOMI with access to its extensive domestic healthcare network.

“We are excited to work with 41 North Partners to increase our healthcare client base in the U.S.,” stated Dr. Halden Shane, TOMI’s Chief Executive Officer. “As we look to further expand our national footprint, we want to ensure we choose the best-positioned partners with which to work. The agreement with 41 North Partners provides us with access to its an extensive network of healthcare sales contacts and partnerships as well as its deep expertise in the industry.

“Throughout 2016, we have been making progress toward capturing share of the U.S. hospital healthcare market. Most notably, in February 2016 we received an amended registration with the EPA, which updates our original registration for our Binary Ionization Technology (BIT™) to include its effectiveness in disinfecting Clostridium difficile spores (C. diff)+, Methicillin Resistant Staphylococcus aureus (MRSA)**and influenza (H1N1)**. Subsequently, our EPA registration amendments were accepted by the states of New York and California, giving TOMI registration in all 50 U.S. states.”

John Stroh, Managing Director of 41 North Partners, stated: “TOMI Environmental Solutions is well equipped to become a leading player in the U.S. healthcare market. Its technology and services provide a very compelling case for hospitals and healthcare facilities around the country to adopt its SteraMist product to control harmful pathogens. We are excited to help support the success of TOMI.”

Source Materials
^*SteraMist™ Surface Unit disinfects Staphylococcus aureus (ATCC # 6538), Pseudomonas aeruginosa (ATCC # 15442), Methicillin Resistant Staphylococcus aureus (MRSA) (ATCC # 33592)
^**Influenza A (H1N1) virus (ATCC VR-1469)
^†SteraMist™ Environment System disinfects Staphylococcus aureus (ATCC # 6538), Pseudomonas aeruginosa (ATCC # 15442), and Clostridium difficile spores (C. diff) (ATCC # 43598)

About TOMI™ Environmental Solutions, Inc.
TOMI^™ Environmental Solutions, Inc. (OTCQX:TOMZ) is a global bacteria decontamination and infectious disease control company, providing eco-friendly environmental solutions for indoor surface decontamination through manufacturing, sales and licensing of our premier platform of Hydrogen Peroxide based products that uses Binary Ionization Technology® (BIT^™), a state of the art technology for the production of its six-log mist represented by the TOMI™ SteraMist™ brand.

TOMI’s products are designed to service a broad spectrum of commercial structures including hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, for non-food safety in meat and produce processing facilities, military barracks, and athletic facilities. TOMI’s products and services have also been used in single-family homes and multi-unit residences.

TOMI also develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, The Restoration Industry Association, Indoor Air Quality Association, and The International Ozone Association. For additional product information, visit www.tomimist.com or contact us at [email protected].

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Certain written and oral statements made by us may constitute “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). Forward-looking statements are identified by such words and phrases as “we expect,” “expected to,” “estimates,” “estimated,” “current outlook,” “we look forward to,” “would equate to,” “projects,” “projections,” “projected to be,” “anticipates,” “anticipated,” “we believe,” “could be,” and other similar phrases. All statements addressing operating performance, events, or developments that we expect or anticipate will occur in the future, including statements relating to revenue growth, earnings, earnings-per-share growth, or similar projections, are forward-looking statements within the meaning of the Reform Act. They are forward-looking, and they should be evaluated in light of important risk factors that could cause our actual results to differ materially from our anticipated results. The information provided in this document is based upon the facts and circumstances known at this time. We undertake no obligation to update these forward-looking statements after the date of this release.

INVESTOR RELATIONS CONTACT:
Becky Herrick & Kirsten Chapman
LHA Investor Relations
(415) 433-3777
[email protected] 

MEDIA RELATIONS CONTACT:
Aaron Loveland
VP of Marketing and Public Affairs
(240) 672-6263
[email protected]